TSE:WLLW

Willow Biosciences Inc. (WLLW.TO) Competitors

C$1.32
-0.01 (-0.75 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
C$1.26
Now: C$1.32
C$1.34
50-Day Range
C$1.29
MA: C$1.48
C$1.80
52-Week Range
C$0.29
Now: C$1.32
C$2.24
Volume124,217 shs
Average Volume476,683 shs
Market CapitalizationC$162.10 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) Vs. RIV, LABS, KHRN, DN, META, and NRTH

Should you be buying WLLW stock or one of its competitors? Companies in the industry of "drug manufacturers—specialty & generic" are considered alternatives and competitors to Willow Biosciences Inc. (WLLW.TO), including RIV Capital (RIV), MediPharm Labs (LABS), Khiron Life Sciences (KHRN), Delta 9 Cannabis (DN), Meta Growth (META), and 48North Cannabis (NRTH).

Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) and RIV Capital (TSE:RIV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for Willow Biosciences Inc. (WLLW.TO) and RIV Capital, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Willow Biosciences Inc. (WLLW.TO)0000N/A
RIV Capital01002.00

Willow Biosciences Inc. (WLLW.TO) presently has a consensus price target of C$2.25, indicating a potential upside of 71.10%. RIV Capital has a consensus price target of C$4.00, indicating a potential upside of 90.48%. Given RIV Capital's higher possible upside, analysts clearly believe RIV Capital is more favorable than Willow Biosciences Inc. (WLLW.TO).

Valuation & Earnings

This table compares Willow Biosciences Inc. (WLLW.TO) and RIV Capital's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Willow Biosciences Inc. (WLLW.TO)C$10,000.0016,209.74C$-51,032,952.00C($0.41)-3.18
RIV CapitalC$15.44 million19.03C$-106,223,568.00C($0.76)-2.77

Willow Biosciences Inc. (WLLW.TO) has higher earnings, but lower revenue than RIV Capital. Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than RIV Capital, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Willow Biosciences Inc. (WLLW.TO) and RIV Capital's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Willow Biosciences Inc. (WLLW.TO)N/AN/AN/A
RIV CapitalN/AN/AN/A

Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Willow Biosciences Inc. (WLLW.TO) and MediPharm Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Willow Biosciences Inc. (WLLW.TO)N/AN/AN/A
MediPharm LabsN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for Willow Biosciences Inc. (WLLW.TO) and MediPharm Labs, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Willow Biosciences Inc. (WLLW.TO)0000N/A
MediPharm Labs02023.00

Willow Biosciences Inc. (WLLW.TO) presently has a consensus target price of C$2.25, suggesting a potential upside of 71.10%. MediPharm Labs has a consensus target price of C$1.53, suggesting a potential upside of 225.53%. Given MediPharm Labs' higher possible upside, analysts plainly believe MediPharm Labs is more favorable than Willow Biosciences Inc. (WLLW.TO).

Earnings & Valuation

This table compares Willow Biosciences Inc. (WLLW.TO) and MediPharm Labs' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Willow Biosciences Inc. (WLLW.TO)C$10,000.0016,209.74C$-51,032,952.00C($0.41)-3.18
MediPharm LabsC$36.01 million3.37C$-123,815,040.00C($0.48)-0.98

Willow Biosciences Inc. (WLLW.TO) has higher earnings, but lower revenue than MediPharm Labs. Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

Summary

MediPharm Labs beats Willow Biosciences Inc. (WLLW.TO) on 4 of the 7 factors compared between the two stocks.

Khiron Life Sciences (CVE:KHRN) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Khiron Life Sciences and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Khiron Life SciencesN/AN/AN/A
Willow Biosciences Inc. (WLLW.TO)N/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Khiron Life Sciences and Willow Biosciences Inc. (WLLW.TO), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Khiron Life Sciences0000N/A
Willow Biosciences Inc. (WLLW.TO)0000N/A

Khiron Life Sciences presently has a consensus price target of C$1.20, suggesting a potential upside of 130.77%. Willow Biosciences Inc. (WLLW.TO) has a consensus price target of C$2.25, suggesting a potential upside of 71.10%. Given Khiron Life Sciences' higher probable upside, equities research analysts clearly believe Khiron Life Sciences is more favorable than Willow Biosciences Inc. (WLLW.TO).

Valuation and Earnings

This table compares Khiron Life Sciences and Willow Biosciences Inc. (WLLW.TO)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Khiron Life SciencesC$8.01 million9.75C$-39,493,921.00C($0.26)-1.98
Willow Biosciences Inc. (WLLW.TO)C$10,000.0016,209.74C$-51,032,952.00C($0.41)-3.18

Khiron Life Sciences has higher revenue and earnings than Willow Biosciences Inc. (WLLW.TO). Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than Khiron Life Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Khiron Life Sciences beats Willow Biosciences Inc. (WLLW.TO) on 5 of the 6 factors compared between the two stocks.

Delta 9 Cannabis (TSE:DN) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Delta 9 Cannabis and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Delta 9 CannabisN/AN/AN/A
Willow Biosciences Inc. (WLLW.TO)N/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Delta 9 Cannabis and Willow Biosciences Inc. (WLLW.TO), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Delta 9 Cannabis00014.00
Willow Biosciences Inc. (WLLW.TO)0000N/A

Delta 9 Cannabis currently has a consensus price target of C$1.10, suggesting a potential upside of 89.66%. Willow Biosciences Inc. (WLLW.TO) has a consensus price target of C$2.25, suggesting a potential upside of 71.10%. Given Delta 9 Cannabis' higher probable upside, analysts clearly believe Delta 9 Cannabis is more favorable than Willow Biosciences Inc. (WLLW.TO).

Earnings & Valuation

This table compares Delta 9 Cannabis and Willow Biosciences Inc. (WLLW.TO)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delta 9 CannabisC$52.05 million1.14C$-7,346,808.00C($0.07)-8.06
Willow Biosciences Inc. (WLLW.TO)C$10,000.0016,209.74C$-51,032,952.00C($0.41)-3.18

Delta 9 Cannabis has higher revenue and earnings than Willow Biosciences Inc. (WLLW.TO). Delta 9 Cannabis is trading at a lower price-to-earnings ratio than Willow Biosciences Inc. (WLLW.TO), indicating that it is currently the more affordable of the two stocks.

Summary

Delta 9 Cannabis beats Willow Biosciences Inc. (WLLW.TO) on 5 of the 7 factors compared between the two stocks.

Meta Growth (CVE:META) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares Meta Growth and Willow Biosciences Inc. (WLLW.TO)'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meta GrowthC$60.96 million0.54C$-50,412,840.00C($0.21)-0.66
Willow Biosciences Inc. (WLLW.TO)C$10,000.0016,209.74C$-51,032,952.00C($0.41)-3.18

Meta Growth has higher revenue and earnings than Willow Biosciences Inc. (WLLW.TO). Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than Meta Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Meta Growth and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Meta GrowthN/AN/AN/A
Willow Biosciences Inc. (WLLW.TO)N/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Meta Growth and Willow Biosciences Inc. (WLLW.TO), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Meta Growth0000N/A
Willow Biosciences Inc. (WLLW.TO)0000N/A

Willow Biosciences Inc. (WLLW.TO) has a consensus price target of C$2.25, suggesting a potential upside of 71.10%. Given Willow Biosciences Inc. (WLLW.TO)'s higher probable upside, analysts plainly believe Willow Biosciences Inc. (WLLW.TO) is more favorable than Meta Growth.

Summary

Meta Growth beats Willow Biosciences Inc. (WLLW.TO) on 4 of the 6 factors compared between the two stocks.

48North Cannabis (CVE:NRTH) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for 48North Cannabis and Willow Biosciences Inc. (WLLW.TO), as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
48North Cannabis0000N/A
Willow Biosciences Inc. (WLLW.TO)0000N/A

Willow Biosciences Inc. (WLLW.TO) has a consensus target price of C$2.25, suggesting a potential upside of 71.10%. Given Willow Biosciences Inc. (WLLW.TO)'s higher probable upside, analysts clearly believe Willow Biosciences Inc. (WLLW.TO) is more favorable than 48North Cannabis.

Earnings and Valuation

This table compares 48North Cannabis and Willow Biosciences Inc. (WLLW.TO)'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
48North CannabisC$17.36 million1.84C$-52,460,873.00C($0.26)-0.61
Willow Biosciences Inc. (WLLW.TO)C$10,000.0016,209.74C$-51,032,952.00C($0.41)-3.18

Willow Biosciences Inc. (WLLW.TO) has lower revenue, but higher earnings than 48North Cannabis. Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than 48North Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares 48North Cannabis and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
48North CannabisN/AN/AN/A
Willow Biosciences Inc. (WLLW.TO)N/AN/AN/A


Willow Biosciences Inc. (WLLW.TO) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
RIV
RIV Capital
0.8$2.10-2.4%C$293.90 millionC$15.44 million-2.77News Coverage
Gap Up
LABS
MediPharm Labs
1.4$0.47-2.1%C$121.24 millionC$36.01 million-0.98Gap Down
KHRN
Khiron Life Sciences
0.9$0.52-3.8%C$67.34 millionC$8.01 million-1.98Gap Down
DN
Delta 9 Cannabis
1.4$0.58-0.0%C$59.18 millionC$52.05 million-8.06News Coverage
META
Meta Growth
0.8$0.14-0.0%C$36.69 millionC$60.96 million-0.66Gap Up
NRTH
48North Cannabis
0.7$0.16-6.3%C$36.44 millionC$17.36 million-0.61
CSI
(CSI)
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
BAMM
28896
0.5N/AN/A$0.00N/A0.00High Trading Volume
ATT
Abattis Bioceuticals
0.5N/AN/AC$0.00N/A0.00Gap Down
AGRA
Agraflora Organics International
1.4N/AN/A$0.00N/A0.00High Trading Volume
GRIN
Grindrod Shipping
1.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
IMCC
IM Cannabis
0.0N/AN/A$0.00N/A0.00High Trading Volume
PULL
Mind Cure Health
1.7N/AN/A$0.00N/A0.00High Trading Volume
SPR
Spirit AeroSystems
0.5N/AN/A$0.00N/A0.00High Trading Volume
BUZZ
VanEck Vectors Social Sentiment ETF
1.0N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
VIDA
Vidaroo
0.5N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.